These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 19043877)

  • 21. Raltegravir, an HIV-1 integrase inhibitor for HIV infection.
    Cabrera C
    Curr Opin Investig Drugs; 2008 Aug; 9(8):885-98. PubMed ID: 18666037
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anti-HIV agents. Merck's integrase inhibitor--short-term efficacy.
    TreatmentUpdate; 2006; 18(5):2-3. PubMed ID: 17205646
    [No Abstract]   [Full Text] [Related]  

  • 23. HIV integrase inhibitors--out of the pipeline and into the clinic.
    Havlir DV
    N Engl J Med; 2008 Jul; 359(4):416-8. PubMed ID: 18650518
    [No Abstract]   [Full Text] [Related]  

  • 24. Selection of the Q148R integrase inhibitor resistance mutation in a failing raltegravir containing regimen.
    Roquebert B; Blum L; Collin G; Damond F; Peytavin G; Leleu J; Matheron S; Chêne G; Brun-Vézinet F; Descamps D;
    AIDS; 2008 Oct; 22(15):2045-6. PubMed ID: 18784469
    [No Abstract]   [Full Text] [Related]  

  • 25. Raltegravir, a new HIV integrase inhibitor.
    Gandhi RT
    AIDS Clin Care; 2007 Dec; 19(12):105. PubMed ID: 18399003
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Raltegravir--beauty and the beast. Both the advantages and the limitations of this integrase inhibitor were evident this year.
    Albrecht H
    J Watch AIDS Clin Care; 2010 Jan; 22(1):4. PubMed ID: 20626067
    [No Abstract]   [Full Text] [Related]  

  • 27. Raltegravir treatment response in an HIV-2 infected patient: a case report.
    Garrett N; Xu L; Smit E; Ferns B; El-Gadi S; Anderson J
    AIDS; 2008 May; 22(9):1091-2. PubMed ID: 18520356
    [No Abstract]   [Full Text] [Related]  

  • 28. Anti-HIV agents. Raltegravir--other issues.
    TreatmentUpdate; 2007 Feb; 19(2):9-10. PubMed ID: 17447317
    [No Abstract]   [Full Text] [Related]  

  • 29. Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection.
    Summa V; Petrocchi A; Bonelli F; Crescenzi B; Donghi M; Ferrara M; Fiore F; Gardelli C; Gonzalez Paz O; Hazuda DJ; Jones P; Kinzel O; Laufer R; Monteagudo E; Muraglia E; Nizi E; Orvieto F; Pace P; Pescatore G; Scarpelli R; Stillmock K; Witmer MV; Rowley M
    J Med Chem; 2008 Sep; 51(18):5843-55. PubMed ID: 18763751
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Raltegravir an integrase inhibitor--a great leap forward within reach].
    Med Monatsschr Pharm; 2007 Nov; 30(11):419-21. PubMed ID: 18062335
    [No Abstract]   [Full Text] [Related]  

  • 31. Exacerbation of depression associated with starting raltegravir: a report of four cases.
    Harris M; Larsen G; Montaner JS
    AIDS; 2008 Sep; 22(14):1890-2. PubMed ID: 18753871
    [No Abstract]   [Full Text] [Related]  

  • 32. Severe rhabdomyolysis associated with raltegravir use.
    Zembower TR; Gerzenshtein L; Coleman K; Palella FJ
    AIDS; 2008 Jul; 22(11):1382-4. PubMed ID: 18580624
    [No Abstract]   [Full Text] [Related]  

  • 33. A case of rhabdomiolysis associated with raltegravir use.
    Dori L; Buonomini AR; Viscione M; Sarmati L; Andreoni M
    AIDS; 2010 Jan; 24(3):473-5. PubMed ID: 20087078
    [No Abstract]   [Full Text] [Related]  

  • 34. FDA notifications. Accelerated approval for raltegravir tablets.
    AIDS Alert; 2007 Dec; 22(12):143-4. PubMed ID: 18411485
    [No Abstract]   [Full Text] [Related]  

  • 35. Trial will evaluate a once-daily dose of raltegravir.
    AIDS Patient Care STDS; 2008 Nov; 22(11):918-9. PubMed ID: 19043842
    [No Abstract]   [Full Text] [Related]  

  • 36. Anti-HIV agents. Integrase inhibitors come of age.
    TreatmentUpdate; 2006; 18(5):1-2. PubMed ID: 17205645
    [No Abstract]   [Full Text] [Related]  

  • 37. The dawn of a new treatment. A look at experimental HIV integrase inhibitors.
    Berger DS
    Posit Aware; 2006; 17(3):44-5. PubMed ID: 16791964
    [No Abstract]   [Full Text] [Related]  

  • 38. Isentress equal to Sustiva in first line therapy.
    Proj Inf Perspect; 2009 Mar; (48):6-7. PubMed ID: 19496211
    [No Abstract]   [Full Text] [Related]  

  • 39. Integrase inhibitor MK-0518: Merck opens expanded-access program.
    James JS
    AIDS Treat News; 2006; (419):5. PubMed ID: 17096488
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dynamic patterns of human immunodeficiency virus type 1 integrase gene evolution in patients failing raltegravir-based salvage therapies.
    Canducci F; Sampaolo M; Marinozzi MC; Boeri E; Spagnuolo V; Galli A; Castagna A; Lazzarin A; Clementi M; Gianotti N
    AIDS; 2009 Feb; 23(4):455-60. PubMed ID: 19165083
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.